Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
CTD_human |
|
|
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Treatment of hepatoma cells with 2-AAF also activated another PI3K downstream effector Akt.
|
11960367 |
2002 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We detected PIK3CA somatic mutations in 26 of 73 hepatocellular carcinomas (35.6%), 25 of 93 breast carcinomas (26.9%), 12 of 185 gastric carcinomas (6.5%), one of 88 acute leukemias (1.1%), and three of 229 non-small-cell lung cancers (1.3%).
|
15608678 |
2005 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Given the prevalence of beta-catenin mutations in many human tumors, especially colon and hepatocellular carcinomas, these data implicate NS5A-mediated PI3K activation as a contributory factor in the increasingly common association between HCV infection and the development of hepatocellular carcinoma.
|
15795286 |
2005 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
Some of the PIK3CA mutations were detected in the early lesions of breast cancer carcinoma, hepatocellular carcinoma, and gastric carcinomas, suggesting that PIK3CA mutation may occur independent of stage of the tumors.
|
15608678 |
2005 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
On the other hand, Akt, the pathway of which can up-regulate HIF-1alpha expression, was activated in the mouse lesions, whereas HIF-1alpha was markedly down-regulated in the mouse hepatocellular carcinoma (HCC) cell lines after treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, indicating that HIF-1alpha expression is dependent on PI3K/Akt signaling.
|
17145871 |
2006 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples.
|
16331247 |
2006 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results are consistent with the possibility that YSV mediates inhibition of tumor growth through inhibition of the PI3K pathway and suggests that YSV should be explored for use as an antitumor agent for hepatocarcinoma.
|
16184552 |
2006 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Taken together, PI3K inhibitors LY294002 and wortmannin up-regulated beta1,4GT1 and enhanced CHX-induced apoptosis in SMMC-7721 cells, which suggested that PI3K inhibitors might have therapeutic potential when combined with CHX in the treatment of hepatoma.
|
17557191 |
2007 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
G2 included HCCs infected with a high copy number of HBV and mutations in PIK3CA and TP53.
|
17187432 |
2007 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
PI3K pathway activation in hepato-biliary carcinomas was analyzed using immunohistochemistry for the downstream targets eIF4-E and phosphorylated 4E-BP1 on tissue microarrays. eIF4-E expression was found in 3/13 intrahepatic CCA (23%), 9/38 extrahepatic CCA (24%), 12/34 gallbladder carcinomas (35%), and 9/61 hepatocellular carcinomas (15%).
|
18181165 |
2008 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
|
17546603 |
2008 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Silencing c-Myc and E2F1 reduced PIK3CA/Akt and mTOR and completely abolished c-Myb and COX-2 expression in human HCC cell lines.
|
18722373 |
2008 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest for the first time that in addition to class I PI3Ks in cancer, class II PIK3C2alpha can modulate HCC cell growth.
|
19591801 |
2009 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Dysregulation of epidermal growth factor and insulin-like growth factor signaling play important roles in human hepatocellular carcinoma (HCC), leading to frequent activation of their downstream targets, the ras/raf/extracellular signal-regulated kinase (ERK) and the phosphoinositide 3-kinase (PI3K)/Akt/mammalian Target of Rapamycin (mTOR) pathways.
|
20860815 |
2010 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Unregulated activation of PI3K/Akt pathway is a prominent feature of many human cancers including human hepatocellular carcinoma (HCC).
|
20506537 |
2010 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Tumor suppression gene PTEN (phosphatase and tensin homolog deleted on chromosome 10), an important antagonist of the phosphoinositide-3-kinase (PI3K)/adenosine triphosphate-dependent tyrosine kinase (Akt) pathway, is also commonly lost or mutated in HCC.
|
20430845 |
2010 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The prosurvival, anti-apoptotic effect of SULF2 in HCC is mediated through activation of the PI3K/Akt pathway.
|
21040406 |
2010 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The tumor suppressor PTEN is a protein/phosphoinositide phosphatase regulating the PI3K/Akt signaling pathway and is mutated or deleted in a variety of human cancers, including hepatocellular carcinoma (HCC).
|
20460918 |
2010 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Here, we provide evidence to illustrate that cytoplasmic AFP may function as a regulator in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in human hepatocellular carcinoma cells.
|
20473866 |
2011 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To evaluate the significance of p-p27 Thr157 and PI3K pathway in hepatocellular carcinoma (HCC), we studied 51 hepatocellular carcinomas along with corresponding nontumoral tissue and the HCC cell lines.
|
20108172 |
2011 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
NVP-BEZ235 is a novel dual inhibitor of PI3K and mTOR; however, its effect on HCC has not been documented.
|
21725613 |
2011 |